Skip to content

Testosterone Cypionate

  • Hormone
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Testosterone Cypionate does in the body

Testosterone replacement therapy

From the FDA-approved label: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · M0XW1UBI14 · read 2026-08-29

  • Its recorded molecular formula is C27H40O3.

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

Where each sentence above came from

No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

No statement of the main limit is recorded.

The four opening statements run to 101 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Stand-in result

A stand-in result is a number measured because the real result takes too long.

A picture of it, and where the picture fails

It is like judging a journey by the speedometer rather than by arriving.

Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.

What people get wrong. A stand-in result is often reported as the result itself.

A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.

Formulation

A formulation is the exact made-up form a substance comes in.

A picture of it, and where the picture fails

It is like the difference between a whole bean and instant coffee.

Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.

What people get wrong. Two products with the same name are assumed to behave the same. They often do not.

The specific composition and physical form of a product, including salt, excipients and release profile.

Receptor

A receptor is a part of a cell that a signal fits into.

A picture of it, and where the picture fails

A receptor is like a lock waiting for one key.

Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.

What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.

A protein that binds a specific ligand and converts that binding into a cellular response.

Pathway

A pathway is a chain of steps inside a cell, each one setting off the next.

A picture of it, and where the picture fails

A pathway is like a row of dominoes.

Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.

What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.

An ordered series of molecular interactions producing a defined cellular change.

What happened in peopleRead from sources, not yet reviewed

What was measured, goal by goal

One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.

Registered studies list 36 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.

There is no single score. A strong test result and a weak life result are different facts.

Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
GoalLife outcomeWhat a body can doHow a person feelsA test resultA step in the bodyHarmsHow longWho was studied
Fertility and sexual healthNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Only a number moved2 registered test measure.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageingWaiting for a reviewer1 registered study measure of this kind. No reviewed result yet.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
MuscleNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Only a number moved1 registered test measure.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Fertility and sexual health
serum testosterone; levels of serum total testosterone concentration; testosterone level
Healthy ageing
frailty phenotype before and after surgery; mortality rate
Muscle
pelvic floor muscle volume

Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.

What each mark on this table means
Nothing in the sources checked
No registered study lists a life outcome for this goal.
Only a number moved
2 registered test measure.
Not recorded
Harms were not a registered measure for this goal.
Waiting for a reviewer
Who was studied is listed further down the page.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Proportion of LPCN 1021-treated subjects who achieve a total testosterone concentration [Cavg] between 300 - 1140 ng/dL.

The study did not show it

Who was studied
NCT02081300
How many people
315
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change in lower limb fat-free mass

The study did not show it

Who was studied
NCT07742553
How many people
300
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Measured performance
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Fatigue change

The study did not show it

Who was studied
NCT04049331
How many people
240
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic Progression

The study did not show it

Who was studied
NCT02286921
How many people
222
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Clinical or Radiographic Progression free survival

The study did not show it

Who was studied
NCT04363164
How many people
150
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Number of participants with changes in 24-hour average systolic ambulatory blood pressure

The study did not show it

Who was studied
NCT07328542
How many people
144
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What happened in peopleRead from sources, not yet reviewed

How close this is to real life

The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.

  1. Living longer, or avoiding a major event Evidence recorded. Death, a heart attack, a stroke, a hospital stay.5 registered measures of this kind. 2 written-up studies measured this and did not show a benefit.
  2. What a body can do day to day No evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
  3. Measured performance No evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
  4. Symptoms and quality of life Evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
  5. A number that stands in for health Evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.4 registered measures of this kind.
  6. A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
  7. Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Rat. A result in animals says what to test next. It does not say what happens in people.
  8. Cells in a dish No evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
  9. A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.

Higher on these steps means closer to something a person would feel. It does not mean better done.

What it would be like to takeRead from sources, not yet reviewed

Felt, measured, or meaningful

Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.

Felt

Things a person could notice without a test.

  • changes in quality of life before and after surgery

Measured

Things only a test, a scale or a device shows.

  • serum testosterone
  • levels of serum total testosterone concentration
  • levels of serum calculated free t concentration
  • pelvic floor muscle volume

Meaningful

Things that change how a life goes, not only a number.

  • clinical or radiographic progression free survival
  • rate of radiographic progression free survival
  • mortality rate
  • clinical/radiographic progression free survival batzen
  • prostate specific antigen progression free survival zenza

A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.

Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.

Measured, but not felt. A number moves. The person notices nothing. Both can be true.

Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.

Matters, but takes years. The result that counts may take longer than anyone would keep watching.

Names that fit none of the three (26)
  • bone metabolism
  • completing at least 3 months of therapy a psa below baseline
  • time to psa progression
  • psa 4 / at the end of the study
  • metabolic equivalent
  • prostate specific antigen response
  • mechanical ventilation dependence
  • evidence of luteal activity
  • american shoulder and elbow
  • simple shoulder test
  • ga68 psma uptake and response to bipolar androgen therapy
  • androgen receptor
  • frailty phenotype before and after surgery
  • major complications
  • minor complications
  • rate of intensive care admission
  • hospital length of stay
  • discharge disposition
  • unplanned readmissions
  • testosterone level

These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • & USAGE AZMIRO is indicated for testosterone replacement therapy in males in conditions associated with a deficiency or absence of endogenous testosterone: • Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchiectomy, Klinefelter’s syndrome, or toxic damage from alcohol or heavy metals,…

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of AZMIRO have not been established in pediatric patients young than 12 years of age.”

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

  • On older people, the label states: “Geriatric patients treated with androgens may be at an increased risk of developing BPH and prostatic carcinoma [see Warnings and Precautions ( 5.3 )].”

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary AZMIRO is contraindicated in pregnant women and not indicated for use in females [see Contraindications ( 4 )].”

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

  • On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Infertility Males During treatment with large doses of exogenous androgens, including AZMIRO, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular-axis [ see Warnings and Precautions ( 5.7 ) ].”

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied for a different goal

The studies measured something else entirely.

On this record: Some registered studies measured things that match no goal on this page.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

A different form was studied

The studied form is not the form on the shelf.

On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Injection

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S3.

No source is stored against this line.

What is in the pack

Sold as injectable, injectable, solution, injection, solution, given by the injection, injection, intramuscular route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Reports sent to a regulator

  • These are reports people sent to a regulator. They do not show the medicine caused the reaction.
  • Nobody counted how many people took the medicine and reported nothing.
  • The same event can be reported more than once, and many reports are incomplete.
  • News coverage, lawsuits and new warnings change how often people report.
  • A count is not a rate and not a risk.

Testosterone Cypionate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1499 reaction mentions were counted. One report can name several reactions.

The recorded terms (10)
  • blood testosterone decreased — 345 reaction mentions
  • deep vein thrombosis — 189 reaction mentions
  • pulmonary embolism — 182 reaction mentions
  • drug abuse — 170 reaction mentions
  • blood testosterone increased — 157 reaction mentions
  • product deposit — 109 reaction mentions
  • myocardial infarction — 108 reaction mentions
  • polycythaemia — 87 reaction mentions
  • acute myocardial infarction — 78 reaction mentions
  • osteonecrosis — 74 reaction mentions
  • open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Injection

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 80 products list this as an active ingredient in the United States drug directory. 80 of them contain it and nothing else.

    FDA National Drug Code directory · 0574-0820 · read 2026-08-29

  • They are sold as injection, injection, solution, powder and solution, taken intramuscular.

    FDA National Drug Code directory · 0574-0820 · read 2026-08-29

  • The regulator's established pharmacologic class for it is androgen receptor agonists [moa], androgen [epc] and androstanes [cs].

    FDA National Drug Code directory · 0574-0820 · read 2026-08-29

  • 42 published labels name it as an active ingredient. 42 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 6bb7d3cc-2b5a-4a48-858e-5421c68b6989 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 6bb7d3cc-2b5a-4a48-858e-5421c68b6989 · read 2026-08-29

  • AZMIRO is intramuscular at 3 DOSAGE FORMS & STRENGTHS Injection: • 200 mg/mL available as 1 mL of clear colorless to pale yellow solution filled in a single-dose glass vial. • 200 mg/mL available as 1 mL of clear colorless to pale yellow solution…, recorded as fda label in effect 2025-07-25 in the United States.

    US prescribing information · 235b5625-570d-3fba-e063-6394a90aa2d1 · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

Names and forms linked to this record

  • Ester of

    Testosterone

    Evidence on this page does not automatically apply to this one.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Testosterone Cypionate studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Testosterone Cypionate are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
M0XW1UBI14
RxNorm concept
835840

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Written into the record, not signed off.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S3.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 20 approved applications cover products containing this substance. The earliest was ANDA086029, approved 19780623 to WATSON LABS.

    Drugs@FDA application register · ANDA086029 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · ANDA086029 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19790725.

    FDA National Drug Code directory · 0574-0820 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

6 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • The path through the body — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (11)

What did Testosterone Cypionate's largest trial (300 people) and its longest (8.2 years) measure?


300 people in Testosterone Cypionate's largest registered study, 8.2 years in its longest registered window, measuring Change in frailty phenotype before and after surgery. ClinicalTrials.gov · 2026-09-01

23 phase2, 5 phase1, 5 phase3, 4 phase4, 2 na, 1 na or unstated; NCT07142551; 2034-06-01. Last human test completed 2026, NCT04895306.

Interpretation These counts include studies where Testosterone Cypionate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.

Show the evidence
  • phase2
    23
  • phase1
    5
  • phase3
    5
  • phase4
    4
  • na
    2
  • na or unstated
    1
1 more recorded row
  • Last recorded human test NCT04895306
    2026-03-27

recorded 2026-09-01 · last checked 2026-09-04

From rat to human: where has Testosterone Cypionate shown healthspan?


rat: mechanism-only and human: healthspan (35): the rungs where Testosterone Cypionate has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01

Interpretation Change in frailty phenotype before and after surgery — the recorded outcome words.

Yeast C. elegans Drosophila Mouse Rat mechanism-onlyDog Non-human primate Human healthspan
Show the evidence
  • rat
    mechanism-only
  • human NCT04731376
    healthspan; Change in frailty phenotype before and after surgery; 35

recorded 2026-09-01 · last checked 2026-09-04

6 of Testosterone Cypionate's trials stopped: accrual/recruitment, funding/business, other?


accrual/recruitment (3), funding/business (1) and other (2): Testosterone Cypionate's stop wording, clustered. ClinicalTrials.gov · 2026-09-01

"No recruitment"; 6 of 35 registered studies

Show the evidence

Trial

  • NCT00853502
    withdrawn; "No recruitment"
  • NCT02803073
    withdrawn; "Subjects could not be recruited"
  • NCT02995330
    terminated; "lack of accrual"
  • NCT04321551
    withdrawn; "study not funded in previous iteration. new clinicaltrials.gov protocol submitted for funded version of study"
  • NCT04345666
    withdrawn; "Unable to obtain funding to complete the study"
  • NCT04551144
    terminated; "lack of recruitment"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Testosterone Cypionate used Testosterone Cypionate 100 MG/ML — over how long?


studies of Testosterone Cypionate used the recorded amount. ClinicalTrials.gov · 2026-09-01

2 recorded entries; human; also "Testosterone Cypionate 100 MG/ML", "Testosterone cypionate (200mg/3ml)"

Show the evidence

human

  • NCT03716739
    Testosterone Cypionate 100 MG/ML
  • NCT06592144
    Testosterone cypionate (200mg/3ml)

recorded 2026-09-01 · last checked 2026-09-04

Which of american shoulder and elbow, androgen receptor and androgen receptor activity did Testosterone Cypionate's trials measure?


american shoulder and elbow, androgen receptor and androgen receptor activity lead 36 outcome terms across Testosterone Cypionate's trials. ClinicalTrials.gov · 2026-09-01

psa 4 / at the end of the study, serum testosterone, metabolic equivalent, prostate specific antigen response, mechanical ventilation dependence and levels of serum total testosterone concentration follow.

Show the evidence
  • bone metabolism
    1
  • completing at least 3 months of therapy a psa below baseline
    1
  • time to psa progression
    1
  • psa 4 / at the end of the study
    1
  • serum testosterone
    1
  • metabolic equivalent
    1
14 more recorded rows
  • prostate specific antigen response
    1
  • mechanical ventilation dependence
    1
  • levels of serum total testosterone concentration
    1
  • levels of serum calculated free t concentration
    1
  • evidence of luteal activity
    1
  • american shoulder and elbow
    1
  • simple shoulder test
    1
  • clinical or radiographic progression free survival
    1
  • ga68 psma uptake and response to bipolar androgen therapy
    1
  • androgen receptor
    1
  • rate of radiographic progression free survival
    1
  • changes in quality of life before and after surgery
    1
  • frailty phenotype before and after surgery
    1
  • major complications
    1

recorded 2026-09-01 · last checked 2026-09-04

Which of Testosterone Cypionate's 14 ongoing trials reports first?


14 registered trials of Testosterone Cypionate are open; earliest completion 2026-11-02. ClinicalTrials.gov · 2026-09-01

Clinical or Radiographic Progression free survival; Changes in quality of life before and after surgery; latest 2034-06-01

Show the evidence

Trial

  • NCT04363164
    "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"; n 150; "Clinical or Radiographic Progression free survival"; 2028-07
  • NCT04731376
    "Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone"; n 56; "Changes in quality of life before and after surgery"; 2026-12-31
  • NCT06039371
    "Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study"; n 69; "Greater than or equal to 50% decline in prostate-specific antigen from baseline (PSA50) response rate"; 2028-11-01
  • NCT06059118
    "Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer"; n 50; "PSA response rate at Cycle 1 Day 64"; 2029-11-30
  • NCT06100705
    "Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC"; n 26; "To determine the immune response to PA2024 with BAT and Sipuleucel-T"; 2028-03
  • NCT06111209
    "The Anabolic Effect of Testosterone on Pelvic Floor Muscles"; n 30; "Change in pelvic floor muscle volume"; 2027-12-01
8 further recorded trials
  • NCT06305598
    "Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer"; n 3; "Androgen receptor (AR) activity"; 2028-03-09
  • NCT06592144
    "TESTO-TRIAL: Use of Testosterone in Critically Ill Patients"; n 94; "Ventilator-free days at 28 days, starting from the date of randomization."; 2026-11-02
  • NCT06922318
    "The COSMYC Trial (COmbined Suppression of MYC)"; n 50; "Clinical/radiographic progression free survival (PFS) with BATZEN"; 2031-08-30
  • NCT07142551
    "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response"; n 60; "Percent of subjects free of Clinical or radiographic free progression"; 2034-06-01
  • NCT07278362
    "Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance"; n 35; "Proportion of Participants with Disease Progression Within 12 Months After Initiating TRT"; 2032-05-31
  • NCT07476001
    "Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC"; n 12; "Feasibility of Tc400 and PSMA-617"; 2027-09
  • NCT07568574
    "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes"; n 60; "The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment."; 2033-03-01
  • NCT07742553
    "Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial"; n 300; "Change in lower limb fat-free mass"; 2032-03-31

recorded 2026-09-01 · last checked 2026-09-04

Which running trial of Testosterone Cypionate could settle lifespan?


NCT04363164 measures Clinical or Radiographic Progression free survival, reading out 2028-07.

2 open trials; n 150; "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"

Show the evidence

Trial

  • NCT04363164
    "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"; n 150; "Clinical or Radiographic Progression free survival"; 2028-07
  • NCT06922318
    "The COSMYC Trial (COmbined Suppression of MYC)"; n 50; "Clinical/radiographic progression free survival (PFS) with BATZEN"; 2031-08-30

Which 3 trials of Testosterone Cypionate posted no result?


Posted no result
3 of 3 completed trials
Registrations
NCT02229617, NCT04424654 and NCT04558866
Completion dates
oldest 2016-05; newest 2024-04-02
Show the evidence

Trial

  • NCT02229617
    2016-05
  • NCT04424654
    2022-07-01
  • NCT04558866
    2024-04-02

At the median, Testosterone Cypionate's trials enrolled 36 people — anything larger?


Median enrolment
36
Largest enrolment
300
Registered trials counted
35

What do 1499 spontaneous reports say about Testosterone Cypionate — and not say?


These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Testosterone Cypionate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1499 reaction mentions were counted: blood testosterone decreased 345; deep vein thrombosis 189; pulmonary embolism 182; drug abuse 170. open-targets-adr · CHEMBL1201101 · 2026-06-24

Show the evidence
  • blood testosterone decreased
    345
  • deep vein thrombosis
    189
  • pulmonary embolism
    182
  • drug abuse
    170
  • blood testosterone increased
    157
  • product deposit
    109
4 more recorded rows
  • myocardial infarction
    108
  • polycythaemia
    87
  • acute myocardial infarction
    78
  • osteonecrosis
    74

recorded 2026-06-24 · last checked 2026-09-04

Was Testosterone Cypionate studied with exercise?


exercise is named in Testosterone Cypionate's label sentences: "Rate and duration of exercise were the same for the last of each subject's several pretreatment tests as for his tests after 4 and 8 weeks of treatment with placebo or testosterone cypionate, 200 mg, intramuscularly weekly." openfda-label+europepmc · 1977-11-01

1 recorded statement; exercise

Show the evidence
  • exercise
    Rate and duration of exercise were the same for the last of each subject's several pretreatment tests as for his tests after 4 and 8 weeks of treatment with placebo or testosterone cypionate, 200 mg, intramuscularly weekly.

recorded 1977-11-01 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1201101
PubChem CID
441404
CAS number
58-20-8
RxCUI
835827
InChIKey
HPFVBGJFAYZEBE-ZLQWOROUSA-N

Relations

Trade name
Andro-cyp, Azmiro, Depotest, Depo-testosterone, Testosterone cypionate component of depo-testadiol, Depo-Testosterone / Azmiro
Development code
NSC-9157
Also called
Testosterone 17.beta.-cyclopentanepropionate, Testosterone cipionate, Testosterone cypionate ciii, high dose testosterone, nandrolone, testosterone, DEPO-TESTADIOL COMPONENT TESTOSTERONE CYPIONATE, TESTOSTERONE 17.BETA.-CYCLOPENTANEPROPIONATE [MI], TESTOSTERONE CIPIONATE [MART.], TESTOSTERONE CYPIONATE CIII [USP-RS], TESTOSTERONE CYPIONATE [ORANGE BOOK], TESTOSTERONE CYPIONATE [USP MONOGRAPH]
Sources (8)

Sources

  • ClinicalTrials.gov clinicaltrials.gov ·
  • ClinicalTrials.gov ClinicalTrials.gov API v2 snapshot 2026-09-01T09:00:05 ·
  • this record's own fields 2,3,5 ·
  • Europe PMC and ClinicalTrials.gov organism ladder ·
  • open-targets-adr CHEMBL1201101 ·
  • openfda-label cfbb53d4-b868-4a28-8436-f9112eb01c39 ·
2 more sources
  • openfda-label+europepmc K1:M0XW1UBI14 ·
  • national registers US, CA ·

ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 8 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.